October 18, 2016 / 6:51 AM / 10 months ago

BRIEF-FDA accepts AstraZeneca's new Hyperkalaemia drug application for review

Oct 18 (Reuters) - AstraZeneca Plc

* FDA accepts for review new drug application for sodium zirconium cyclosilicate (zs-9) for the treatment of Hyperkalaemia

* FDA has indicated that this is a complete class 2 response

* Interactions with other health authorities in European Union and Australia are ongoing with decisions expected in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below